The TransPORTEC, an international consortium related to the Post Operative Radiation Therapy for Endometrial Cancer (PORTEC) 3 trial, identified four new subgroups of high-risk EC: a POLE proofreading mutant group, a p53 mutant group, a microsatellite instable group, and a group with no specific molecular profile [10]. The gene discussed is POLE; the disease is endometrial cancer.